Edition:
United States

Checkpoint Therapeutics Inc (CKPT.OQ)

CKPT.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
4:00pm EDT
Change (% chg)

$0.03 (+1.05%)
Prev Close
$2.86
Open
$2.87
Day's High
$2.92
Day's Low
$2.68
Volume
26,689
Avg. Vol
31,658
52-wk High
$7.06
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Checkpoint Therapeutics Announces Encouraging Safety And Efficacy Data From Phase 1/2 Clinical Trial Of Egfr Inhibitor Ck-101
Thursday, 6 Sep 2018 07:30am EDT 

Sept 6 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS ANNOUNCES ENCOURAGING SAFETY AND EFFICACY DATA FROM PHASE 1/2 CLINICAL TRIAL OF EGFR INHIBITOR CK-101.CHECKPOINT THERAPEUTICS INC - PHASE 3 TRIAL IN TREATMENT-NAÏVE EGFR MUTATION-POSITIVE NSCLC PATIENTS TARGETED TO COMMENCE IN 2019.CHECKPOINT THERAPEUTICS INC - EGFR INHIBITOR CK-101 WELL-TOLERATED WITH UNREMARKABLE SAFETY PROFILE.  Full Article

Checkpoint Therapeutics Reports Q4 Results
Thursday, 15 Mar 2018 04:05pm EDT 

March 15 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.CHECKPOINT THERAPEUTICS INC - ‍AS OF DECEMBER 31, 2017, CHECKPOINT'S CASH AND CASH EQUIVALENTS TOTALED $19.2 MILLION​.  Full Article

Checkpoint Therapeutics Announces Pricing Of Public Offering Of Common Stock
Thursday, 8 Mar 2018 09:00am EST 

March 8 (Reuters) - Checkpoint Therapeutics Inc ::CHECKPOINT THERAPEUTICS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING OF 4.60 MILLION COMMON SHARES PRICED AT $4.35PER SHARE.  Full Article

Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:44pm EST 

Nov 9 (Reuters) - Checkpoint Therapeutics Inc :Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​.  Full Article

Checkpoint Therapeutics receives orphan drug designation for CK-101
Monday, 11 Sep 2017 08:30am EDT 

Sept 11 (Reuters) - Checkpoint Therapeutics Inc ::Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer.Checkpoint Therapeutics Inc - ‍ck-101 is currently being studied in phase 1 dose-escalation portion of a phase 1/2 clinical study​.  Full Article